Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p??(I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds FAP; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.

Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p ??(I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds FAP; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.

Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds FAP; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.

Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds Endoglin; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.

Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds Endoglin; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.

Abstract: The present invention relates to conjugates, in particular antibody-drug conjugates and immunotoxins, having the formula I: A-(L-D)p (I) or a pharmaceutically acceptable salts or solvates thereof, wherein: A is an antibody that selectively binds FAP; L is a linker; D is a drug comprising a cytolysin or a Nigrin-b A-chain; and p is 1 to 10, and to use of such conjugates in the therapeutic treatment of tumors. Methods of producing such conjugates and components for use in such methods are disclosed.

Abstract: The invention relates to a method of storing and/or transporting in vitro two-dimensional cell cultures. The inventive method comprises the following steps consisting in: a) coating a cell culture that is immobilized on an asymmetric support with a gelatine solution in culture medium at a concentration of between 1 and 5%; b) solidifying the gelatine added to the support at a temperature of between 15 and 25° C.; and c) storing and/or transporting the cell culture at a temperature of between 15 and 25° C. for a period of up to 96 hours. The invention also relates to a kit which is used to store and/or transport the in vitro two-dimensional cell cultures according to the inventive method, said kit comprising: i) an asymmetric support, and (ii) a gelatine solution in culture medium at a concentration of between 1 and 5%.

Abstract: The present invention relates to a box for transporting samples, conceived to maintain the temperature in its interior in a range between 15° C. and 25° C. for an extended time period and suitable for any product that requires thermal and mechanical resistance, particularly for biological samples. The transport box of the invention comprises a series of non-primary packaging of carefully selected dimensions, shape and materials, accumulating heat elements and, optionally, filling material.

Abstract: The invention relates to a method of storing and/or transporting in vitro two-dimensional cell cultures. The inventive method comprises the following steps consisting in: a) coating a cell culture that is immobilised on an asymmetric support with a gelatine solution in culture medium at a concentration of between 1 and 5%; b) solidifying the gelatine added to the support at a temperature of between 15 and 25° C.; and c) storing and/or transporting the cell culture at a temperature of between 15 and 25° C. for a period of up to 96 hours. The invention also relates to a kit which is used to store and/or transport the in vitro two-dimensional cell cultures according to the inventive method, said kit comprising: i) an asymmetric support, and (ii) a gelatine solution in culture medium at a concentration of between 1 and 5%.